Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 18, 2017 07:30 ET | Source: Marinus Pharmaceuticals, Inc.

Marinus to present Ganaxolone DATA at American academy of neurology annual meeting

Platform Presentation of Phase 2 Data in Fragile X Syndrome RADNOR, Pa., April 18, 2017 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the...
April 11, 2017 07:30 ET | Source: Marinus Pharmaceuticals, Inc.

Dr. Lorianne K. Masuoka Joins Marinus Pharmaceuticals as Chief Medical Officer

RADNOR, Pa., April 11, 2017 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and...
April 10, 2017 07:30 ET | Source: Marinus Pharmaceuticals, Inc.

Ganaxolone IV Clinical Data Presented at Leading International Status Epilepticus Medical Conference

RADNOR, Pa., April 10, 2017 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and...
March 15, 2017 07:30 ET | Source: Marinus Pharmaceuticals, Inc.

Marinus Pharmaceuticals to Present at Oppenheimer Healthcare Conference

RADNOR, Pa., March 15, 2017 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and...
March 13, 2017 07:30 ET | Source: Marinus Pharmaceuticals, Inc.

Marinus Pharmaceuticals Provides Business Update and 2016 Financial Results

RADNOR, Pa., March 13, 2017 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and...
February 14, 2017 07:30 ET | Source: Marinus Pharmaceuticals, Inc.

Ganaxolone Reduces Seizures and Improves Behaviors in Angelman Syndrome Preclinical Model

Data Published in NeuropharmacologyRADNOR, Pa., Feb. 14, 2017 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative...
February 01, 2017 07:30 ET | Source: Marinus Pharmaceuticals, Inc.

Marinus Appoints Michael R. Dougherty to its Board of Directors

RADNOR, Pa., Feb. 01, 2017 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and...
January 23, 2017 07:30 ET | Source: Marinus Pharmaceuticals, Inc.

Marinus Announces Positive Preliminary Data From Children With CDKL5 Genetic Disorder

Plans to Apply for Orphan Drug Designation RADNOR, Pa., Jan. 23, 2017 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), today announced positive preliminary data from the initial...
January 05, 2017 07:30 ET | Source: Marinus Pharmaceuticals, Inc.

Marinus Provides Business Outlook for 2017

Several Data Milestones Anticipated With Ganaxolone RADNOR, Pa., Jan. 05, 2017 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the...
January 03, 2017 07:30 ET | Source: Marinus Pharmaceuticals, Inc.

Marinus Pharmaceuticals Receives FDA Orphan Drug Designation for Ganaxolone to Treat Fragile X Syndrome

RADNOR, Pa., Jan. 03, 2017 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and...